Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

VY7523-102: A Randomized, Placebo-Controlled, Double-Blind Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of Multiple Ascending Intravenous Doses of VY7523 in Participants With Early Alzheimer's Disease

NCT06874621 is registered in ClinicalTrials.gov with Voyager Therapeutics as lead sponsor.

NCT NCT06874621
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06874621 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
VY7523-102: A Randomized, Placebo-Controlled, Double-Blind Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of Multiple Ascending Intravenous Doses of VY7523 in Participants With Early Alzheimer's Disease
Lead sponsor
Voyager Therapeutics
Phase
Phase 1/2
Overall status
Active, not recruiting
Start date
March 3, 2025
Completion date
May 31, 2027
Enrollment
52 (estimated)
Sites
23

Conditions

As the registry lists them; a condition with its own page is linked.

alzheimer's disease (ad)